Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: A critical role of the angiotensin II/AT1 receptor axis

Circulation Research

Volumn 110, Issue 10, 2012, Pages 1322-1335

  Patel, Vaibhav B ^a   Bodiga, Sreedhar ^a   Basu, Ratnadeep ^a   Das, Subhash K ^a   Wang, Wang ^a   Wang, Zuocheng ^c   Lo, Jennifer ^a   Grant, Maria B ^b   Zhong, Jiuchang ^a   Kassiri, Zamaneh ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF FLORIDA   (United States)

^c NONE

Author keywords

angiotensin II; angiotensin converting enzyme 2; AT1 receptor; diabetes; renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 7; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; COLLAGENASE 3; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; IRBESARTAN; JANUS KINASE 2; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUTROPHIL COLLAGENASE; PROTEIN KINASE B; PROTEIN KINASE C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DOWN REGULATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HYPERGLYCEMIA; IN VIVO STUDY; KNOCKOUT MOUSE; LIPOTOXICITY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; VASCULAR DISEASE; VASODILATATION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIABETIC ANGIOPATHIES; FEMALE; GENE EXPRESSION; HEART FAILURE, SYSTOLIC; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION;

EID: 84861099242     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.268029     Document Type: Article

References (61)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974;34:29-34.
2. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146. (Pubitemid 29416243)
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787. (Pubitemid 34000780)
4. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213-3223.
5. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010;55:300-305.
6. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006;98:596-605.
7. Falcao-Pires I, Hamdani N, Borbely A, Gavina C, Schalkwijk CG, van der Velden J, van Heerebeek L, Stienen GJ, Niessen HW, Leite-Moreira AF, Paulus WJ. Diabetes mellitus worsens diastolic left ventricular dys- function in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011;124:1151-1159.
8. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123-1132.
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869.
10. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126. (Pubitemid 40432462)
11. Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlof B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol. 2005;96: 1530-1536. (Pubitemid 41690173)
12. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, Scholey JW, Penninger JM, Oudit GY. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2:446-455.
13. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis and cardiac dysfunction. Circulation. 2010;122:717-728, 18 p following 728.
14. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, Guo D, Holland SM, Scholey JW, Penninger JM, Kassiri Z, Oudit GY. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit. Cardiovasc Res. 2011;91: 151-161.
15. Wang W, Bodiga S, Das SK, Lo J, Patel V, Oudit GY. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev. 2011 Jun 3 [Epub ahead of print].
16. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, Kassiri Z. Type 1 diabetic cardiomyopathy in the Akita (Ins2wt/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol. 2009;297: H2096-H2108.
17. Heiss C, Sievers RE, Amabile N, Momma TY, Chen Q, Natarajan S, Yeghiazarians Y, Springer ML. In vivo measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound. Am J Physiol Heart Circ Physiol. 2008;294:H1086-H1093. (Pubitemid 351253323)
18. Guo D, Kassiri Z, Basu R, Chow FL, Kandalam V, Damilano F, Liang W, Izumo S, Hirsch E, Penninger JM, Backx PH, Oudit GY. Loss of PI3K{gamma} enhances camp-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res. 2010;107:1275-1289.
19. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z. TIMP2 deficiency accelerates adverse postmyocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res. 2010;106:796-808.
20. Kandalam V, Basu R, Abraham T, Wang X, Awad A, Wang W, Lopaschuk GD, Maeda N, Oudit GY, Kassiri Z. Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol Heart Circ Physiol. 2010;299:H1012-H1023.
21. Mehta PK, Griendling KK. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97. (Pubitemid 46127306)
22. Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A. 2004;101:13302-13305. (Pubitemid 39209660)
23. Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY, Kim JH, Sumner AD, Vary TC, Gardner TW, Bronson SK, Kim JK. Nonobese, insulindeficient Ins2akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling. Am J Physiol Endocrinol Metab. 2007;293:E1687-E1696. (Pubitemid 350255120)
24. Ishii H, Koya D, King GL. Protein kinase c activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med (Berl). 1998;76:21-31. (Pubitemid 28085058)
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. (Pubitemid 34000785)
26. Geraldes P, King GL. Activation of protein kinase c isoforms and its impact on diabetic complications. Circ Res. 106:1319-1331.
27. Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res. 2008;79:238-248. (Pubitemid 351951609)
28. Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res. 2009;82:250-260.
29. Sartoretto JL, Kalwa H, Pluth MD, Lippard SJ, Michel T. Hydrogen peroxide differentially modulates cardiac myocyte nitric oxide synthesis. Proc Natl Acad Sci U S A. 2011;108:15792-15797.
30. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M. Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: Potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. Mol Genet Metab. 1998;65:181-186. (Pubitemid 28507139)
31. 2+- independent alterations in diastolic sarcomere length and relaxation kinetics in a mouse model of lipotoxic diabetic cardiomyopathy. Circ Res. 2009;104:95-103.
32. Schmidt U, del Monte F, Miyamoto MI, Matsui T, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation. 2000;101:790-796. (Pubitemid 30100087)
33. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51: 1166-1171. (Pubitemid 34438364)
34. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: Role of the AT1 receptor and NADPH oxidase. Hypertension. 2003;42: 206-212. (Pubitemid 36944598)
35. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: Animal and human studies. Circulation. 2003;108:2034-2040. (Pubitemid 37337574)
36. Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian GH, Scholz GH. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension. 2002;39:756-760. (Pubitemid 34252870)
37. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev. 2007;87: 1285-1342. (Pubitemid 350041472)
38. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-2588. (Pubitemid 35386893)
39. Xu J, Zou MH. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation. 2009;120:1266-1286.
40. Shivu GN, Phan TT, Abozguia K, Ahmed I, Wagenmakers A, Henning A, Narendran P, Stevens M, Frenneaux M. Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus. Circulation. 2010;121:1209-1215.
41. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
42. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: An inconvenient truth! J Am Coll Cardiol. 2010;55: 526-537.
43. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate at1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol. 2003;284:H846-H852. (Pubitemid 36228231)
44. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM, Scholey JW. Loss of angiotensinconverting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol. 2007;171:438-451. (Pubitemid 47344677)
45. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286: 421-426. (Pubitemid 32681484)
46. Allred AJ, Diz DI, Ferrario CM, Chappell MC. Pathways for angiotensin-( 1-7) metabolism in pulmonary and renal tissues. Am J Physiol Renal Physiol. 2000;279:F841-F850.
47. Chappell MC, Allred AJ, Ferrario CM. Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant. 2001;16 (Suppl 1):22-26. (Pubitemid 32492500)
48. Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1-R13. (Pubitemid 36736490)
49. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM, Grant PJ. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35:1031-1040.
50. Noland TA Jr, Kuo JF. Protein kinase c phosphorylation of cardiac troponin i or troponin t inhibits Ca2(+)-stimulated actomyosin MgATPase activity. J Biol Chem. 1991;266:4974-4978. (Pubitemid 21909450)
51. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A. 2002;99:12333-12338.
52. Moore L, Fan D, Basu R, Kandalam V, Kassiri Z. Tissue inhibitor of metalloproteinases (TIMPS) in heart failure. Heart Fail Rev. 2011 Jun 30 [Epub ahead of print].
53. Cheung N, Bluemke DA, Klein R, Sharrett AR, Islam FM, Cotch MF, Klein BE, Criqui MH, Wong TY. Retinal arteriolar narrowing and left ventricular remodeling: The multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2007;50:48-55. (Pubitemid 46963526)
54. Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J. 1980;99:446-458. (Pubitemid 10009592)
55. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288: 373-376. (Pubitemid 11169009)
56. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension. 1986;8: 37-44. (Pubitemid 16161419)
57. Cooke JP, Rossitch E Jr, Andon NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 1991;88:1663-1671.
58. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
59. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension. 2001;37: 1047-1052. (Pubitemid 32304002)
60. Loot AE, Schreiber JG, Fisslthaler B, Fleming I. Angiotensin ii impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med. 2009;206:2889-2896.
61. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: Linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488-496. (Pubitemid 351651106)